Abetimus

Abetimus (trade name Riquent) is an immunosuppressant.^[1] It is a synthetic biological called a tolerogen. It is made of four double-stranded oligodeoxyribonucleotides that are attached to a carrier platform and are designed to block specific B-cell anti double stranded DNA antibodies.^[2] It may also complex anti dsDNA antibodies together, therefore disabling them. This way abetimus was supposed to help treat systemic lupus erythematosus and specifically lupus nephritis.

Abetimus sodium

Clinical data
Trade names	Riquent
ATC code	L04AA22 (WHO)
Identifiers
CAS Number	169147-32-4 N
PubChem SID	17397358
ChemSpider	none
UNII	F5Y7739G6U
KEGG	D03204 N
Chemical and physical data
Formula	C1632H1944N610Na156O970P156S4
Molar mass	54171.35 g·mol−1
NY (what is this?)  (verify)

It was developed by La Jolla Pharmaceutical, who applied for marketing authorisations in the mid-2000s, but the drug was never marketed in the US or in Europe.^[3][4]